Index to Research – List of Investigators
Kristy M. Ainslie: Dr. Ainslie’s research objectives focus on the integration of micro/nanotechnology and microfabrication therapeutics towards developing applied and translational therapies. Her areas of direct application include but are not limited to the fields of drug delivery and applied immunology.
Lai-Sim Au: pharmacodynamics of anticancer and anti-AIDS
drugs in cultured cells, tissues, animals and patients; with
an emphasis on treatment of bladder, head and neck, prostate,
breast, and ovarian cancer.
John A. Bauer: the roles and mechanisms of nitric oxide
control in disease, especailly cardiovascular disease / cardiovascular
complications associated with congestive heart failure, diabetes,
and AIDS / nitric oxide control in urological complications
Stuart J. Beatty: pharmacist reimbursement, primary/ambulatory Care, pain management, educational technology.
C. Brackett: infectious disease, AIDS, and optimizing
Brueggemeier: the role of steroids in the growth of
breast cancer and in the development of drugs that interfere
with hormone action / aromatase inhibitors.
professional ethics and pharmacy practice, the history of
pharmacy in the United States, and pharmacy education.
Esperanza J. Carcache de Blanco dietary supplements, traditional medicine, natural products drug discovery.
cardiovascular pharmacology / electrophysiological effects
of drugs that act on the heart.
K. Chan: applications of stable isotopes in pharmacokinetics,
metabolism and mechanism of action; alkylating agents / cancer
chemotherapy and drug development / liposome drug formulation
/ analytical method development / mass spectrometry.
Chen: mechanism-based design of novel therapeutic
agents that selectively target apoptosis machinery in cancer
cells at cellular or epigenetic levels
D. Coyle: drug therapy in patients with kidney disease,
including those on dialysis. His goal is to help patients
and their healthcare providers achieve targeted therapeutic
outcomes using a comprehensive pharmacotherapeutic approach,
including application of clinical pharmacokinetic and dynamic
principles. Treatment of hypertension in renal failure patients
is of particular interest.
W. Curley, Jr.: the use of vitamin A and its retinoid
analogues as anticancer agents / stereoselective syntheses
of stable isotope-labeled amino acids and NMR studies of drug
receptor interactions / carotenoid cleavage products and metabolites and their biological importance.
T. Dalton: ligand binding domains of androgen, glucocorticoid,
progesterone, and estrogen receptors.
F. Dasta: critical care pharmacy, critical care health
outcomes and pharmacokinetics.
G. Frank: design and evaluation of drug delivery systems,
with an emphasis on emulsions, liposomes, and liquid crystals
/ micelle stability and solubilization, small-particle formation
and microencapsulation, iontophoresis, percolation theory,
and fractal geometry.
James R. Fuchs: major areas of emphasis of our lab are in the preparation of novel antibiotics and anticancer agents with unique or interesting mechanisms of action through selective inhibition of a specific protein or enzyme target. We will utilize synthetic methods to prepare bioactive natural products and their analogues to gain insight into the structure-activity relationships of ligand/receptor systems, and investigate biosynthetic pathways.
L. Hayton: (Professor Emeritus) minimizing environment toxicity through
understanding pharmacokinetics and metabolism of aquatic species.
Hinkle: nuclear pharmacy with emphasis on the medical
use of radionuclides and radiolabeled antibodies.
G. Hoyt: regulation of DNA damage and programmed cell
death (apoptosis) by matrix and soluble factors in the extracellular
environment / signal transduction processes that lead to adverse
effects of drugs.
Kari Hoyt: the molecular mechanisms underlying the loss of neurons in neurodegenerative diseases.
Keli Hu: The long-term research interest in Dr. Hu's laboratory is to study the function and regulation of metabolically-sensitive ion channels using cellular and molecular approaches, with a special emphasis on traffic regulation, molecular mechanisms and their physiological relevance, particularly as these processes relate to human diseases.
A. Douglas Kinghorn: research interests include the discovery of natural product lead compounds from tropical rainforest plants, particularly those with potential anticancer, cancer chemopreventive, and oral antimicrobial activity. He is also interested in the scientific evaluation of botanical dietary supplements and the development of potently sweet substances of natural origin.
L. Knoell: studies the lung microenvironment with
a particular emphasis on host response during inflammatory
stress. Investigations incorporate human lung epithelial cell
culture, animal and human studies and aspects of immunology
as well as cellular and molecular biology. The most current
studies aim to improve our understanding of emphysema and
Nicole C. Kwiek: improving science education through novel curricular and outreach initiatives.
Veronique LaCombe: the goals of my NIH-funded research program are to study glucose metabolism and fuel selection in striated muscles and to better understand the pathogenesis of cardiovascular complications of metabolic diseases, using an integrative and translational approach.
J. Lee: Delivery of anticancer agents via targeted liposomes or nanoparticles. Therapeutic delivery of genes, antisense oligonucleotides, CpG oligos, siRNA, miRNA, and anti-miRs. Receptor targeted bioconjugates for cancer therapy. Nanomedicines for cancer and leukemia therapy. Targeted delivery to AML, CLL, HCC, breast, GBM, etc. Translational research.
Chenglong Li: Structure-based and computer-aided drug design and discovery (SBDD/CADD), molecular docking, molecular dynamics, computational chemistry, X-ray protein crystallography, Anti-cancer, anti-diabetic and anti-infectious molecular design and simulation.
Zhongfa Liu: Identification and Validation of Protein and DNA adducts as Epigenetic Biomarkers and Their Modulation by Dietary Supplements for Chemoprevention and Therapy / Preclinical and Clinical Pharmacokinetics, Metabolite and Pharmacodynamics / Drug Analytical Method Development / Mass Spectrometry/ SMEDDS.
(Tom) Li: drug development (steroid sulfatase inhibitors)
for the treatment of breast cancer / designing melatonin analogs
to elucidate the physiological roles of melatonin in humans.
M. McAuley: We are working on many new and exciting
projects in our expansive laboratory, also known as the outpatient
epilepsy clinic. My research focus is the patient with epilepsy.
We have a particular focus on women's issues in epilepsy.
We have projects looking at the influence of hormones on seizure
activity, how pregnancy influences epilepsy and its' treatments,
and many more. We have a new clinic with the High Risk OB
practitioners providing collaborative pharmaceutical care
for pregnant women with epilepsy. There is an intriguing relationship
between folate and antiepileptic drugs that has become a recent
focus of efforts. Another new project is looking at how we
can convert a "pharmacoresistant" patient to someone
more sensitive to therapy. Other projects include assessing
knowledge about epilepsy by patients and healthcare professionals.
The interested student(s) may take on a portion of one of
these as their project or develop their own. The many fascinating
aspects of clinical research will be discovered.
B. McKay: The primary focus of our laboratory is on drug discovery. Our target for drug discovery is the nicotinic receptor. Nicotinic receptors and their many subtypes are linked to a number of neurological diseases such as schizophrenia, attention deficit hyperactivity disorder, Alzheimer's disease, Tourette's syndrome, Parkinson's disease, autism, and some types of epilepsy.
Jay M. Mirtallo: safety and efficacy of parenteral nutrition, parenteral nutrition in obesity, outcomes and issues with long-term parenteral nutrition, innovative health-system pharmacy programs.
C. Nahata: pediatric and antimicrobial pharmacokinetics
N. Patil: (Professor Emeritus) autonomic nervous system pharmacology with
emphasis on steric aspects of drug receptor interactions,
desensitization, morphology of sensory and synaptic receptors
/ ocular pharmacology, and drug melanin interactions.
Mitch Phelps: Pre-clinical and clinical pharmacokinetics of anti-cancer agents and the role of polymorphisms in transporters and metabolizing enzymes in drug disposition and clinical outcomes.
Maria Pruchnicki: areas of interest include ambulatory care and chronic disease management, pharmacokinetics, and pharmacy education, including educational technology and distance learning.
W. Robertson: fermentation and microbial products,
microbiological transformations of drugs, antibiotics, drug
metabolism, metabolism and biological activities of cannabinoids.
Thomas D. Schmittgen:
development of new cancer therapies or diagnostics, gene expression, targeted drug delivery for cancer therapy. Areas of study include: 1) development of RNA aptamers as targeting agents for prostate and breast cancer; 2) quantitative PCR as a tool to study gene expression in cancerous and noncancerous tissues; 3) role of small, noncoding (i.e. micro RNAs) in cancer development.
L. Szeinbach: distribution of pharmaceutical products
and services / service delivery decision-making processes
that involve utility analysis (pharmacoeconomics) and risk
assessment / organizational structure, automation, and information
Tjarks: Nucleosides for anticancer- and antiviral therapy.
James A. Visconti:
drug information / infectious disease therapeutics.
J. Wallace: mechanisms by which abused drugs change
the brain and its response to drugs / neurodegenerative diseases
/ bladder dysfunction in diabetes.
discovery and development of drugs to treat disease caused
by parasitic organisms.
Guillaume Wientjes: pharmacokinetics and pharmacodynamics
of drugs for bladder and prostate cancer in patients, animals,
and cell culture / use of regional and targeted drug delivery.
P. Young: molecular and cellular pharmacology / regulation
of glutamine synthetase gene expression during retinal development,
glucocorticoid-mediated muscle atrophy, and nitric oxide synthase